— FHIM's Mission —

An international platform connecting senior decision-makers.

FHIM connects senior decision-makers across the EMEA, Chinese and wider Asian healthcare innovation, investment and policy ecosystems.

Help shape the future of healthcare through strategic cooperation between the two regions.

STRATEGIC INITIATIVE

Support the creation of dedicated cross-border fund-of-funds, designed to accelerate healthcare innovation and deployment between EMEA, China & Wider Asia.

BEYOND CAPITAL

FHIM seeks to contribute to a broader ambition: Building a healthier, more innovative, and more interconnected global healthcare future.

500+ Delegates

Highly quantitative profile of senior cross-border decision-makers.

50% Healthcare Companies

C-level executives from established pharmaceuticals, innovative biotechnology, medical technology innovators, and healthcare providers.

40% Investors

Active cross-border allocators, limited partners (LPs), general partners (GPs), and strategic pharma corporate venture capital.

10% Policy & Regulation

Government authorities, regulatory overseers, and specialized industry trade networks.

Why China?

The World's Fastest-Evolving Healthcare Innovation Ecosystem

$569T

Record 2025 R&D Spend

$130B+

Out-Licensing Volume

70%

Global Biotech BD Value Share

• A global leader in healthcare innovation across biotech, medtech, AI, robotics, and digital health.

• World-class clinical resources, rapid development timelines, and an increasingly innovation-driven regulatory environment.

• Unmatched manufacturing capabilities and supply chain efficiency.

• China is no longer only a healthcare market, it is becoming a global source of healthcare innovation and value creation.

Why EMEA?

Capital, Expertise & Global Reach

$1.5T

Sector Value Contribution

$13.2B

VC Biotech Inflows

15%

Global Health R&D Hubs